Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT04538755
PHASE1/PHASE2

DAW2020 on OSA Endotypic Traits

Sponsor: Brigham and Women's Hospital

View on ClinicalTrials.gov

Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. Some OSA patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (UA) dilator muscle recruitment. As a consequence they are exposed to apnea and hypopnea cycling. In this protocol the investigators will test the effect of DAW2020 administered before sleep on OSA phenotype traits and OSA severity during sleep.

Official title: Effect of DAW2020 on Endotypic Traits in OSA

Key Details

Gender

All

Age Range

21 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2020-11-15

Completion Date

2026-12-15

Last Updated

2026-07-15

Healthy Volunteers

No

Interventions

DRUG

Placebo oral capsule

Placebo before sleep

DRUG

DAW2020 oral capsule

DAW2020 34 mg 4 h before sleep, single night administration

Locations (1)

Brigham and Women's Hospital

Boston, Massachusetts, United States